Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug Application (NDA) submitted to U.S. Food and Drug Administration TETON study of Tyvaso in idiopathic pulmonary fibrosis (IPF) expected to enroll its first patients in the second quarter of 2021 SILVER SPRING, […]
Other News
Ionis reports first quarter 2021 financial results and recent business achievements
On track to achieve 2021 guidance Webcast today, May 5, 2021, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 5, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2021 and recent business highlights. “In the first quarter, we took important steps to maximize […]
TransMedics Reports First Quarter 2021 Financial Results
ANDOVER, Mass., May 4, 2021 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2021. Recent Highlights Net revenue of $7.1 million in the first quarter of 2021, […]
ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets – – Secured Major Medicare Part D Contract Covering Approximately 8.5 Million Lives – – […]
Resverlogix Announces US$6 Million Debenture Financing
CALGARY, Alberta, May 05, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announces that it has entered into an investment agreement with a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink”) which provides for Hepalink to purchase 10% secured convertible debentures of the Company […]
Aziyo Biologics Reports First Quarter 2021 Financial Results and Increases 2021 Revenue Guidance
SILVER SPRING, Md., May 04, 2021 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three months ended March 31, 2021. Recent Highlights Recorded […]
HeartFlow and MedAxiom Announce Collaboration to Improve Care Delivery for Patients with Coronary Artery Disease
REDWOOD CITY, Calif. & NEPTUNE BEACH, Fla.–(BUSINESS WIRE)–HeartFlow, Inc., a leader in revolutionizing precision heartcare, and MedAxiom, an American College of Cardiology (ACC) company whose mission is to transform cardiovascular care and improve heart health, announced today a collaboration to improve cardiovascular care for patients with coronary artery disease (CAD). The […]
Verve Therapeutics Appoints Industry Leader Sheila Mikhail to its Board of Directors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sheila Mikhail, J.D., MBA, chief executive officer and co-founder of Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, has joined the company’s board of […]
The Feasibility of 12-Lead Computational Analysis in Patients after COVID-19 Infection, using Vektor Medical’s vMap™, presented at Taiwan Heart Rhythm Society (THRS) 2021 Cutting-Edge Care for Heart Rhythm
vMap™ was presented as a technology that was able to provide arrhythmia insights for patients following COVID-19 infection, beyond those available from a standard 12-lead ECG CARLSBAD, Calif.–(BUSINESS WIRE)–Vektor Medical, Inc. announced that a single-center study conducted at the University of California San Diego reports that use of vMap™ (computational 12-lead ECG analysis) […]
Robocath successfully completes first robotic coronary angioplasties in Belgium
Rouen, France, May 4, 2021 – Robocath, a company that designs, develops and commercializes cardiovascular robotic platforms for the treatment of vascular diseases, today announces the successful completion of first five robotic coronary angioplasties in Belgium. The Percutaneous Coronary Interventions (PCI) were performed on April 8 and 13 by Prof. Stefan Verheye, […]



